OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies to drive drug discovery in high definition, today announced the appointment of Dr Nathalie Franchimont as a Non-Executive Director. Nathalie brings more than 15 years of leadership experience in biotechnology and pharma industries.
“We are delighted to welcome Nathalie to our Board of Directors,” said Dr Edward Hodgkin, Chairman, OMass Therapeutics and Partner at Syncona Investment Management Limited. “Nathalie is a highly accomplished leader in our industry with extensive drug development experience and immunology expertise. We look forward to drawing on Nathalie’s expertise as we continue to expand and progress our portfolio of programmes in immunology and genetically defined diseases.”
Nathalie currently leads development in Multiple Sclerosis and Immunology at Biogen, as VP, Head of MS and Immunology Development Unit. She has also previously held a variety of leadership roles at Biogen, including leading the Multiple Sclerosis Research and Early Development Unit, the New Indications Research and Early Development Unit and the Immunology Drug Innovation Unit. Prior to joining Biogen, Nathalie held Medical Affairs and Clinical Research roles at Amgen.
Nathalie is a rheumatologist; she trained as a M.D., Ph.D. at the University of Liège and has held research fellowship roles at the University of Connecticut School of Medicine, Yale University School of Medicine and University of Liège.
Nathalie Franchimont, commented:
“I am delighted to join the Board of Directors of OMass at an exciting time in the company’s development when its high-resolution biophysical screening platform is yielding some promising new compounds across a growing portfolio of early programmes. I look forward to contributing to ongoing discussions on translation from bench science to the clinic, and ultimately to making real differences in the lives of patients.”